Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and
EGFR
cell toxicity
gefitinib
in-vitro
inhibitors
side effects
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
08
2022
accepted:
20
10
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
3
12
2022
Statut:
epublish
Résumé
Alterations to the EGFR (epidermal growth factor receptor) gene, which primarily occur in the axon 18-21 position, have been linked to a variety of cancers, including ovarian, breast, colon, and lung cancer. The use of TK inhibitors (gefitinib, erlotinib, lapatinib, and afatinib) and monoclonal antibodies (cetuximab, panitumumab, and matuzumab) in the treatment of advanced-stage cancer is very common. These drugs are becoming less effective in EGFR targeted cancer treatment and developing resistance to cancer cell eradication, which sometimes necessitates stopping treatment due to the side effects. One
Identifiants
pubmed: 36457709
doi: 10.3389/fphar.2022.1027890
pii: 1027890
pmc: PMC9707641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1027890Informations de copyright
Copyright © 2022 Opo, Moulay, Zari, Alqaderi, Alkarim, Zari, Bhuiyan, Mahmoud, Aljoud, Suhail, Edris, Ramadan, Kamal, Nemmiche and Ahammad.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W409-14
pubmed: 22553363
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S235-S246
pubmed: 31857948
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Int J Mol Sci. 2020 Oct 21;21(20):
pubmed: 33096664
PLoS One. 2015 Aug 12;10(8):e0134398
pubmed: 26267891
J Pharm Anal. 2018 Oct;8(5):307-311
pubmed: 30345144
J Chem Inf Model. 2014 Mar 24;54(3):902-12
pubmed: 24555519
Front Chem. 2022 Oct 04;10:986376
pubmed: 36267655
J Recept Signal Transduct Res. 2019 Feb;39(1):18-27
pubmed: 31223050
Int J Biol Macromol. 2021 Nov 30;191:1114-1125
pubmed: 34592225
PLoS One. 2017 May 2;12(5):e0176403
pubmed: 28463978
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
pubmed: 18227510
Methods Mol Biol. 2015;1263:243-50
pubmed: 25618350
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
Lung Cancer. 2020 Apr;142:41-46
pubmed: 32088604
Cell Death Differ. 2013 Jan;20(1):64-76
pubmed: 22858544
Cell. 2009 Jun 26;137(7):1293-307
pubmed: 19563760
J Recept Signal Transduct Res. 2017 Dec;37(6):600-610
pubmed: 28958213
Sci Rep. 2021 Feb 18;11(1):4049
pubmed: 33603068
J Chem Inf Model. 2005 Jan-Feb;45(1):160-9
pubmed: 15667141
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Transl Lung Cancer Res. 2021 Mar;10(3):1277-1291
pubmed: 33889509
World J Clin Oncol. 2015 Oct 10;6(5):133-41
pubmed: 26468449
J Chem Inf Model. 2012 Jul 23;52(7):1757-68
pubmed: 22587354
Front Oncol. 2019 Aug 23;9:800
pubmed: 31508364
J Med Chem. 2012 Jul 26;55(14):6582-94
pubmed: 22716043
J Hematol Oncol. 2022 Jul 15;15(1):94
pubmed: 35840984
Nucleic Acids Res. 2015 Jul 1;43(W1):W612-20
pubmed: 25883136
Methods Mol Biol. 2017;1611:109-122
pubmed: 28451975
Healthcare (Basel). 2022 Feb 24;10(3):
pubmed: 35326902
Cochrane Database Syst Rev. 2017 Jun 27;6:CD007047
pubmed: 28654140
Sci Rep. 2015 Feb 03;5:7835
pubmed: 25644501
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Front Oncol. 2020 Jan 14;9:1503
pubmed: 31993373
SAR QSAR Environ Res. 2017 Jun;28(6):525-539
pubmed: 28703021
J Breast Cancer. 2017 Jun;20(2):150-159
pubmed: 28690651
Nucleic Acids Res. 2010 Jan;38(Database issue):D255-66
pubmed: 19933261
J Thorac Dis. 2018 Mar;10(3):1431-1439
pubmed: 29707292
Clin Cancer Res. 2006 Nov 1;12(21):6494-501
pubmed: 17085664
Nature. 2011 Mar 24;471(7339):523-6
pubmed: 21430781
PLoS One. 2020 Feb 13;15(2):e0228925
pubmed: 32053675
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Curr Comput Aided Drug Des. 2011 Jun;7(2):146-57
pubmed: 21534921
Br J Pharmacol. 2011 Mar;162(6):1239-49
pubmed: 21091654
J Cancer. 2011;2:435-42
pubmed: 21850211
Curr Oncol. 2011 Jun;18(3):126-38
pubmed: 21655159
Brief Bioinform. 2009 Sep;10(5):579-91
pubmed: 19433475
J Cell Physiol. 2006 May;207(2):420-7
pubmed: 16419029
Cell. 2012 Nov 21;151(5):937-50
pubmed: 23178117
Br J Clin Pharmacol. 2014 Dec;78(6):1185-200
pubmed: 25041729
Molecules. 2021 Nov 04;26(21):
pubmed: 34771085
Adv Bioinformatics. 2016;2016:9258578
pubmed: 27190510
Mar Drugs. 2021 Apr 28;19(5):
pubmed: 33925208
J Recept Signal Transduct Res. 2018 Feb;38(1):48-60
pubmed: 29369008
Patholog Res Int. 2011 Feb 14;2011:932932
pubmed: 21403829
J Biomed Nanotechnol. 2021 Nov 1;17(11):2153-2164
pubmed: 34906276
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
Cancer Cell. 2007 Mar;11(3):217-27
pubmed: 17349580
Chin J Cancer. 2011 Jan;30(1):5-12
pubmed: 21192840
Oncogene. 2000 Dec 27;19(56):6574-83
pubmed: 11426642
Int J Mol Sci. 2022 Mar 23;23(7):
pubmed: 35408854
Arch Pharm Res. 2015 Sep;38(9):1686-701
pubmed: 26208641
Curr Pharm Des. 2016;22(5):572-81
pubmed: 26601966
Nucleic Acids Res. 2018 Jul 2;46(W1):W257-W263
pubmed: 29718510
Ann Oncol. 2005 Feb;16(2):189-94
pubmed: 15668269
J Clin Oncol. 2011 Jul 20;29(21):2866-74
pubmed: 21670455
J Med Chem. 2020 Aug 13;63(15):8502-8511
pubmed: 32672461